1037797-53-7

Upstream product

• 1037791-31-3 4-[4-(4-tetrazol-1-ylphenoxymethyl)thiazol-2-yl]piperidine-1-carboxylic acid tert-butyl ester 
• 39546-32-2 4-carboxamidopiperidine 

Downstream Products

• 1037793-42-2 4-[4-(4-tetrazol-1-ylphenoxymethyl)thiazol-2-yl]piperidine-1-carboxamidine 
• 1044136-60-8 4-[4-(4-tetrazol-1-ylphenoxymethyl)thiazol-2-yl]piperidine-1-carbonitrile 
• 1037792-44-1 5-ethyl-2-{4-[4-({[4-(1H-tetrazol-1-yl)phenyl]oxy}methyl)-1,3-thiazol-2-yl]-1-piperidinyl}pyrimidine 
• 1037793-40-0 4-[4-(4-tetrazol-1-ylphenoxymethyl)thiazol-2-yl]piperidine-1-carboxylic acid amide 
• 1037793-31-9 1-(3-isopropyl-[1,2,4]oxadiazol-5-yl)-4-[4-(4-tetrazol-1-ylphenoxymethyl)thiazol-2-yl]piperidine 

Relevant academic research and scientific papers

Synthesis and biological evaluation of thiazole derivatives as GPR119 agonists

A series of 4-(phenoxymethyl)thiazole derivatives was synthesized and evaluated for their GPR119 agonistic effect. Several 4-(phenoxymethyl)thiazoles with pyrrolidine-2,5-dione moieties showed potent GPR119 agonistic activities. Among them, compound 27 and 32d showed good in vitro activity with an EC50 value of 49 nM and 18 nM, respectively with improved human and rat liver microsomal stability compare with MBX-2982. Compound 27 & 32d did not exhibit significant CYP inhibition, hERG binding, and cytotoxicity. Moreover, these compounds lowered the glucose excursion in mice in an oral glucose-tolerance test.

COMPOSITIONS OF 5-ETHYL-2--PYRIMIDINE

This invention relates to the field of pharmaceutical chemistry and, more specifically, to pharmaceutical formulations as well as to intermediates used to prepare such formulations and to methods for manufacturing such formulations.

PREPARATION OF 5-ETHYL-2-{4-[4-(4-TETRAZOL-1-YL-PHENOXYMETHYL)-THIAZOL-2-YL]-PIPERIDIN-1-YL}-PYRIMIDINE

Processes and intermediates for the synthesis of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine are provided.

HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS

Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active.